{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:11:54Z","timestamp":1792401114795,"version":"4.4.0"},"reference-count":55,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Phytotherapy has long represented a widely accepted treatment alternative to conventional therapy. Bitter melon is a vine with potent antitumor effects against numerous cancer entities. To date, no review article has, however, been published on the role of bitter melon in breast and gynecological cancer prevention and therapy. The current work constitutes the most comprehensive, up-to-date review of the literature, which highlights the promising anticancer effects of bitter melon on breast, ovarian, and cervical cancer cells and discusses future research recommendations.<\/jats:p>","DOI":"10.3390\/ijms24108918","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:09:44Z","timestamp":1684397384000},"page":"8918","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-6242","authenticated-orcid":false,"given":"Iason","family":"Psilopatis","sequence":"first","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleio","family":"Vrettou","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-4831","authenticated-orcid":false,"given":"Constantinos","family":"Giaginis","sequence":"additional","affiliation":[{"name":"Department of Food Science and Nutrition, School of Environment, University of Aegean, 81400 Lemnos, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Theocharis","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"ref_1","unstructured":"CDC (2023, April 15). Complementary and Alternative Medicine: Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/cancer\/survivors\/patients\/complementary-alternative-medicine.htm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5217\/ir.2020.00150","article-title":"Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: Results of a cross-sectional, multinational study","volume":"20","author":"Kim","year":"2022","journal-title":"Intest. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/heapol\/czw022","article-title":"Use of traditional medicine in middle-income countries: A WHO-SAGE study","volume":"31","author":"Oyebode","year":"2016","journal-title":"Health Policy Plan."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sur, S., and Ray, R.B. (2020). Bitter Melon (Momordica charantia), a Nutraceutical Approach for Cancer Prevention and Therapy. Cancers, 12.","DOI":"10.3390\/cancers12082064"},{"key":"ref_5","first-page":"81","article-title":"Bitter melon: A panacea for inflammation and cancer","volume":"14","author":"Dandawate","year":"2016","journal-title":"Chin. J. Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2016.07.002","article-title":"Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy","volume":"40\u201341","author":"Raina","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s43014-022-00089-x","article-title":"A comprehensive review on bitter gourd (Momordica charantia L.) as a gold mine of functional bioactive components for therapeutic foods","volume":"4","author":"Gayathry","year":"2022","journal-title":"Food Prod. Process. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/CLEP.S330081","article-title":"Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980\u20132018)","volume":"14","author":"Piechocki","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"ref_9","unstructured":"CDC (2023, April 15). Gynecologic Cancer Incidence, United States\u20142012\u20132016: Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no11-gynecologic-cancer-incidence-UnitedStates-2012-2016.htm."},{"key":"ref_10","unstructured":"ACS (2023, April 15). Key Statistics for Breast Cancer: American Cancer Society. Available online: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html."},{"key":"ref_11","first-page":"12","article-title":"Diverse roles of bitter melon (Momordica charantia) in prevention of oral cancer","volume":"7","author":"Sur","year":"2021","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.15430\/JCP.2021.26.4.266","article-title":"Comparative Pre-clinical Efficacy of Chinese and Indian Cultivars of Bitter Melon (Momordica charantia) against Pancreatic Cancer","volume":"26","author":"Kandhari","year":"2021","journal-title":"J. Cancer Prev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sur, S., Steele, R., Isbell, T.S., Venkata, K.N., Rateb, M.E., and Ray, R.B. (2021). Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling. Cancers, 13.","DOI":"10.3390\/cancers13061432"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1574892818666221103114649","article-title":"Ribosome-inactivating protein MAP30 isolated from Momordica charantia L. induces apoptosis in hepatocellular carcinoma cells","volume":"18","author":"Zhao","year":"2022","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1089\/dna.2020.5469","article-title":"MAP30 Inhibits Bladder Cancer Cell Migration and Invasion In Vitro Through Suppressing Akt Pathway and the Epithelial\/Mesenchymal Transition Process","volume":"39","author":"Zhang","year":"2020","journal-title":"DNA Cell Biol."},{"key":"ref_16","first-page":"1171","article-title":"In-vitro antitumor-activity of the plant ribosome-inactivating proteins map-30 and gap-31","volume":"5","author":"Rybak","year":"1994","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1006\/bbrc.1999.1213","article-title":"Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active","volume":"262","author":"Huang","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","first-page":"653","article-title":"Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30","volume":"20","author":"Sun","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22419","DOI":"10.1038\/srep22419","article-title":"A triterpenoid from wild bitter gourd inhibits breast cancer cells","volume":"6","author":"Bai","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"935675","DOI":"10.1155\/2013\/935675","article-title":"Cucurbitane Triterpenoid from Momordica charantia Induces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated Receptor gamma Activation","volume":"2013","author":"Weng","year":"2013","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/ptr.5900","article-title":"Identification of a Triterpenoid as a Novel PPARgamma Activator Derived from Formosan Plants","volume":"31","author":"Weng","year":"2017","journal-title":"Phytother. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.prostaglandins.2019.03.005","article-title":"Mammary cancer risk and serum lipid profile of rats supplemented with pomegranate seed oil and bitter melon extract","volume":"142","author":"Lepionka","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105057","DOI":"10.1016\/j.chemphyslip.2021.105057","article-title":"Oxysterols and lipidomic profile of myocardium of rats supplemented with pomegranate seed oil and\/or bitter melon aqueous extract\u2014Cardio-oncological animal model research","volume":"235","author":"Lepionka","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.fitote.2014.11.009","article-title":"Alpha-momorcharin (alpha-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo","volume":"100","author":"Cao","year":"2015","journal-title":"Fitoterapia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10717544.2014.905652","article-title":"PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo","volume":"23","author":"Deng","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10495-011-0684-z","article-title":"RNase MC2: A new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways","volume":"17","author":"Fang","year":"2012","journal-title":"Apoptosis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"114036","DOI":"10.1016\/j.jep.2021.114036","article-title":"Momordica charantia L. induces non-apoptotic cell death in human MDA-MB-436 breast and A549 lung cancer cells by disrupting energy metabolism and exacerbating reactive oxygen species\u2019 generation","volume":"277","author":"Ehigie","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/1940-6207.CAPR-09-0088","article-title":"Eleostearic Acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism","volume":"2","author":"Grossmann","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"66226","DOI":"10.18632\/oncotarget.19887","article-title":"Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death","volume":"8","author":"Muhammad","year":"2017","journal-title":"Oncotarget"},{"key":"ref_30","first-page":"1925","article-title":"Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis","volume":"70","author":"Ray","year":"2010","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1142\/S0192415X02000302","article-title":"Effects of bitter melon (Momordica charantia L.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice","volume":"30","author":"Nagasawa","year":"2002","journal-title":"Am. J. Chin. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Feng, T., Wan, Y., Dai, B., and Liu, Y. (2023). Anticancer Activity of Bitter Melon-Derived Vesicles Extract against Breast Cancer. Cells, 12.","DOI":"10.3390\/cells12060824"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/mc.22882","article-title":"Disrupting cholesterol esterification by bitter melon suppresses triple-negative breast cancer cell growth","volume":"57","author":"Shim","year":"2018","journal-title":"Mol. Carcinog."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2174\/1871520620666200424124746","article-title":"The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of (99m)Tc Labeled Paclitaxel: In Vitro Monitoring in Breast Cancer Cells","volume":"20","author":"Kilcar","year":"2020","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11010-018-3464-z","article-title":"Bitter taste receptors are expressed in human epithelial ovarian and prostate cancers cells and noscapine stimulation impacts cell survival","volume":"454","author":"Martin","year":"2019","journal-title":"Mol. Cell Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105157","DOI":"10.1016\/j.phrs.2020.105157","article-title":"MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis","volume":"161","author":"Chan","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11418-017-1099-0","article-title":"Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells","volume":"71","author":"Pitchakarn","year":"2017","journal-title":"J. Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1534735415611747","article-title":"Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade","volume":"15","author":"Yung","year":"2016","journal-title":"Integr. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-004-0848-4","article-title":"Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract","volume":"54","author":"Limtrakul","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jnutbio.2010.11.005","article-title":"Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance","volume":"23","author":"Pitchakarn","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"ref_41","first-page":"61","article-title":"Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy","volume":"86","author":"Pongnikorn","year":"2003","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1142\/S0192415X21500737","article-title":"Efficacy and Safety of Chinese Herbal Medicine on Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials","volume":"49","author":"Ho","year":"2021","journal-title":"Am. J. Chin. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.31557\/APJCP.2022.23.1.261","article-title":"A Phytochemicals Approach Towards the Treatment of Cervical Cancer Using Polyphenols and Flavonoids","volume":"23","author":"Yadav","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1002\/cnr2.1312","article-title":"Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital","volume":"4","author":"Ramasubbu","year":"2021","journal-title":"Cancer Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zari, A.T., Zari, T.A., and Hakeem, K.R. (2021). Anticancer Properties of Eugenol: A Review. Molecules, 26.","DOI":"10.3390\/molecules26237407"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113760","DOI":"10.1016\/j.biopha.2022.113760","article-title":"Phytotherapeutic applications of alkaloids in treating breast cancer","volume":"155","author":"Rampogu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chota, A., George, B.P., and Abrahamse, H. (2020). Potential Treatment of Breast and Lung Cancer Using Dicoma anomala, an African Medicinal Plant. Molecules, 25.","DOI":"10.3390\/molecules25194435"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopha.2018.01.030","article-title":"Corilagin, a promising medicinal herbal agent","volume":"99","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1517\/13543784.2013.811486","article-title":"Plants and cervical cancer: An overview","volume":"22","author":"Wang","year":"2013","journal-title":"Expert Opin. Investig. Drugs."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Garmpis, N., Damaskos, C., Dimitroulis, D., Kouraklis, G., Garmpi, A., Sarantis, P., Koustas, E., Patsouras, A., Psilopatis, I., and Antoniou, E.A. (2022). Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101672"},{"key":"ref_52","first-page":"299","article-title":"Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises","volume":"14","author":"Garmpis","year":"2017","journal-title":"Cancer Genom. Proteom."},{"key":"ref_53","first-page":"950","article-title":"Targeting histone deacetylases in endometrial cancer: A paradigm-shifting therapeutic strategy?","volume":"22","author":"Garmpis","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7850688","DOI":"10.1155\/2021\/7850688","article-title":"Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma","volume":"2021","author":"Psilopatis","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Psilopatis, I., Garmpis, N., Garmpi, A., Vrettou, K., Sarantis, P., Koustas, E., Antoniou, E.A., Dimitroulis, D., Kouraklis, G., and Karamouzis, M.V. (2023). The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy. Cancers, 15.","DOI":"10.3390\/cancers15082222"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8918\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:37:12Z","timestamp":1760125032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24108918"],"URL":"https:\/\/doi.org\/10.3390\/ijms24108918","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]}}}